摘要
目的(1)总结中西医对狼疮性肾炎(LN)的发病机制和防治措施的研究进展；(2)观察清热解毒活血中药对瘀热痹阻证LN的临床疗效。(3)观察Ⅳ型LN患者血清对正常人肾小球系膜细胞(GMC)增殖的影响以及清热解毒活血中药对Ⅳ型LN血清干预下GMC增殖、细胞凋亡、GMC中Bcl-2蛋白合成和Bcl-2mRNA表达的影响，从细胞分子生物学水平探讨清热解毒活血中药治疗LN的机制，为临床应用提供实验依据。
方法(1)文献研究：通过查阅大量古代和现代中、西医国内外文献，总结和评价有关LN的中医认识、病因病机、西医发病机制以及中西医防治措施方面的研究现状。(2)临床研究：用简单随机化、前瞻性的研究方法，将60例瘀热痹阻证LN患者按1：1比例分为对照组和治疗组。对照组采用常规西医治疗，治疗组在对照组的基础上加用清热解毒活血中药治疗，3月为一疗程。观察患者主要症状、证候(面部红斑、发热、口疮、双手红斑、关节疼痛、关节肿胀、肌肉疼痛、脱发、浮肿、胸痛、心悸、乏力、烦躁、手足心热、口干、失眠、耳鸣、痤疮、咽痛、月经血块)和实验室检查指标(白细胞、淋巴细胞、血红蛋白、血小板、尿白细胞、尿红细胞、尿蛋白、尿素氮、肌酐、血浆白蛋白、血沉、C_3、C_4、CH_(50)、抗核抗体、抗双链DNA抗体(抗ds-DNA抗体)、凝血功能等)的改善情况，计算治疗前后的狼疮活动评分(SLEDAI)和中医证候积分，评定疾病疗效和证候疗效。(3)实验研究：①将正常对照血清和不同浓度(5％、10％、15％、20％)的Ⅳ型LN患者的血清作用于GMC，观察其对GMC增殖的影响，并选择对GMC增殖影响最显著的一组血清(x％)用于下一步的实验。②结合血清药理学方法，分为5组进行观察(Ⅰ组为空白对照组、Ⅱ组为对照组血清+x％LN血清组、Ⅲ、Ⅳ、Ⅴ组分别为低、中、高浓度含药血清+x％LN血清组)，分别采用MTT法检测GMC的增殖及抑制率，荧光法和流式细胞仪技术检测GMC细胞凋亡。③再将实验分为5组进行，1组为空白对照组、2组为对照组血清+x％LN血清组、3、4、5组分别为低、中、高浓度含药血清+x％LN血清组，采用western blot检测GMC中抑凋亡基因Bcl-2蛋白的合成、采用逆转录-多聚酶链反应(RT-PCR)测定Bcl-2mRNA的表达。
结果(1)文献研究：①病名：根据狼疮性肾炎的临床表现可归属于中医“阴阳毒”、“红蝴蝶疮”、“阳毒发斑”、“痹证”、“水肿”、“虚劳(肾劳)”等范畴。②病因病机：肝肾阴虚、热毒血瘀为瘀热痹阻证LN的病机特点。③治疗：主要分为分型论治、分期论治、中成药治疗、自拟方治疗、单味药或中药提取物治疗、中药注射液治疗及其它疗法，取得较好的疗效，目前多数学者采用清热解毒活血法为主治疗LN。④现代医学研究：LN发病复杂，与遗传因素(遗传易感因素等)、GMC增殖及凋亡异常、免疫调节功能异常(细胞因子网络失衡、自身抗体如抗ds-DNA抗体、抗心磷脂抗体等的产生和免疫复合物清除能力下降等)以及神经、内分泌、代谢因素等有关，其中，肾小球固有细胞如GMC增殖、凋亡异常是LN发生、发展的重要机制，因此，防治措施力图抑制肾小球固有细胞如GMC的增殖、诱导细胞凋亡。治疗上有糖皮质激素、免疫抑制剂、其它疗法(血浆置换、免疫吸咐疗法、免疫球蛋白)等，但西医治疗存在着治疗方案不规范、部分患者对治疗不敏感或产生耐药、副作用大等缺点，因此，研究疗效确切、经济、副作用较小的中医药治疗方案成为当前临床研究的重点。(2)临床研究：治疗组疾病疗效评定总有效率和证候疗效评定总有效率分别为83.33％、93.33％，疾病疗效高于对照组，差异无统计学意义(P＞0.05)，证候疗效明显高于对照组，差异有非常显著性意义(P＜0.01)。治疗组治疗后SLEDAI和中医证候积分较治疗前均明显减少，差异有非常显著性意义(P均＜0.01)；治疗组治疗后SLEDAI的降低优于对照组，但无统计学意义(P＞0.05)，中医证候积分较对照组明显降低，差异有非常显著性意义(P＜0.01)。二组患者的LN主症较治疗前均可明显减轻，差异有非常显著性意义(P均＜0.01)，且治疗组治疗后LN主症的改善作用优于对照组，但差异无统计学意义(P＞0.05)，与对照组相比患者的烦躁、咽痛、痤疮、月经血块、口干、手足心热、耳鸣、心悸症状也明显减轻，差异有非常显著性意义(P均＜0.01)。在实验室检查方面，治疗组患者治疗后白细胞、淋巴细胞、血红蛋白、血小板、血浆白蛋白、C_3、C_4、CH_(50)明显升高，尿红细胞、尿蛋白、ANA滴度、血沉、血浆纤维蛋白原明显降低，抗ds-DNA抗体转阴的作用也较明显，与治疗前相比，差异均有非常显著性意义(P均＜0.01)；其中，在降低血沉、抗ds-DNA抗体转阴方面的作用优于对照组，差异有显著性意义(P＜0.05)。(3)实验研究：①Ⅳ型LN患者血清对GMC增殖的影响：发现不同浓度(5％、10％、15％、20％)的Ⅳ型LN血清均可明显促进GMC增殖，与对照血清相比有非常显著性差异(P＜0.01)，其中以15％Ⅳ型LN患者血清最为显著。②观察清热解毒活血中药对GMC增殖和凋亡的影响：在15％Ⅳ型LN患者血清干预下，不同浓度(低、中、高浓度)的含药血清均可明显抑制GMC的增殖、诱导GMC的细胞凋亡，与对照组血清相比差异有非常显著性意义(P＜0.01)，其作用呈较明显的量效关系，其中，以高浓度含药血清组的上述作用最为显著，与其余各组比较差异均有非常显著性意义(P均＜0.01)。③GMC中B细胞淋巴瘤／白血病-2(Bcl-2)蛋白合成、Bcl-2mRNA表达的检测：对照血清组的Bcl-2蛋白合成、Bcl-2mRNA的表达比空白对照组显著增强；而在15％Ⅳ型LN患者的血清干预下，不同浓度(低、中、高浓度)的清热解毒活血中药的含药血清与对照组血清相比均可明显抑制GMC中抑凋亡基因Bcl-2蛋白合成和Bcl-2mRNA的表达，其作用呈较明显的量效关系，其中，以高浓度含药血清组的上述作用最为显著。
结论(1)LN的发病机制较为复杂，GMC增殖、细胞凋亡异常是LN发病的重要机制；西医治疗存在部分患者不敏感、副作用大等缺点，研究能抑制GMC增殖、诱导GMC细胞凋亡的中药具有广阔的研究的临床应用前景。(2)临床研究显示：清热解毒活血中药不仅可以显著改善瘀热痹阻证LN的主症，改善各项标示狼疮活动的实验室检查指标，而且可以明显减少SLEDAI和中医证候积分，对瘀热痹阻证LN有较好的治疗作用，副作用小。(3)实验研究发现：Ⅳ型LN患者血清可明显促进GMC的增殖，以15％Ⅳ型LN患者血清最为明显。而清热解毒活血中药的含药血清可明显抑制15％Ⅳ型LN患者血清干预下的GMC增殖、诱导GMC的细胞凋亡、抑制抑凋亡基因Bcl-2蛋白的合成、下调Bcl-2mRNA的表达，这可能是清热解毒活血中药治疗LN的分子机理，从而为临床广泛应用提供了实验和理论依据。
Objective (1) To sum up the progress of the research on the pathogenic mechanismand prevention measures of Lupus Nephritis (LN) in traditional Chinese andWestern medical sciences. (2) To observe the clinical therapeutic effects onLN of toxic heat and blood stagnation with the method of heat-clearing,detoxifying and promoting blood flow (HCDP). (3) To observe the effects ofblood serum of type-ⅣLN patients on glomerular mesangial cell (GMC)proliferation of healthy people. To observe the effects of Chinese crude drugof HCDP on GMC proliferation and apoptosis, Bcl-2 protein synthesis andBcl-2mRNA expression. To explore the mechanism of the method of heat-clearing,detoxifying and promoting blood flow (HCDP) on the level of cell and molecularbiology and to provide experimental evidence for clinical application.
Methods (1) Literature study: To consult a large number of ancient and modernresearch documents about Chinese and Western medical sciences, summarize andassess traditional Chinese medical science-oriented understanding,etiopathogenisis and Western medical science-oriented pathogenesis of LN, aswell as the status quo of researches into prevention and cure measures. (2)Clinical research: Sixty patients with LN of toxic heat and blood stagnationwere randomly and equally divided into a control group and a subject group.The control group adopted treatment of western medicine, while the subjectgroup was offered the method of heat-clearing, detoxifying and promoting bloodflow (HCDP) on top of western medicine. The period of treatment was three months.Cardinal symptoms included: erythema on face, febricity, aphtha, erythema onhands, arthralgia, arthrocele, myalgia, alopecia, puffiness, chest pain,palpitation, hypodynamia, dysphoria, feverish sensation in palms and soles, xerostomia, insomnia, tinnitus, ache, pharyngalgia and menstrual clots.Laboratory index contained: white blood cell (WBC), lymphocyte (LYMN),hemoglobin (HGB), platelet (PLT), urinary leukocyte (LEU), urinaryerythrocyte (ERY), urinary protein (PRO), blood urea nitrogen (BUN), serumcreatinine (Cr), plasma albumin (ALB), erythrocyte sedimentation rate (ESR),C_3, C_4, CH_(50), antinuclear antibody (ANA), anti-ds-DNA antibody, and bloodcoagulation function (including fibrinogen, FIB), etc. The Systemic LupusErythematosus Disease Activity Index (SLEDAI) and the integral syndrome ofTCM before and after the therapy were calculated. Therapeutic effect on thedisease and syndrome were respectively evaluated. (3) Empirical study:①Serum of healthy adults and serum of different concentration (5%, 10%, 15%and 20%) of type-ⅣLN patients were used to affect GMC, and their effectson GMC proliferation were observed. The serum (x%) whose effect on promotingGMC proliferation was the most significant was selected for the next experiment.②With the method of blood serum pharmacology, 5 groups were observed:group-Ⅰ: blank, group-Ⅱ: control serum+x% serum of type-ⅣLN patients,group-Ⅲ: low concentration serum which contained Chinese medicine of HCDP+x% serum of type-ⅣLN patients, group-Ⅳ: medium concentration serum whichcontained Chinese medicine of HCDP+x% serum of type-ⅣLN patients, group-Ⅴ: high concentration serum which contained Chinese medicine of HCDP+x%serum of type-ⅣLN patients. MTT method was adopted to detect theproliferation and inhibition ratios of GMC. Apoptosis of GMC were detectedwith the fluorometric method and flow cytometer respectively.③Afterwards,the methods of western blot and RT-PCR were respectively used to detectsynthesis of Bcl-2 protein and expression of Bcl-2mRNA , which was the genein GMC inhibiting apoptosis, by 5 groups (group-1: blank, group-2: controlserum+x% serum of type-ⅣLN patients, group-3、4、5: low、medium and highconcentration serum which contained Chinese medicine of HCDP+x% serum oftype-ⅣLN patients respectively).
Results (1)Study on publications:①Name: According to clinical manifestations,LN was discovered in diseases described in traditional Chinese medicalsciences, such as "toxin of Yin-Yang", "red butterfly-shaped sore","patch of Yang toxin", "arthromyodynia", "edema", "kidney deficiency"and so on.②Etiopathogenisis and pathogenesis: The etiopathogenisis andpathogenesis of LN of toxic heat and blood stagnation was summarized as Yin asthenia of liver and kidney, toxic heat and blood stagnation.③Therapy: Themain TCM therapeutic methods of LN include: treatment by types, by stages,by Chinese patent medicine, by private prescription, by a single medicinalherb, by extract from or injection of traditional Chinese medicine, etc. Thetherapeutic effects on LN are satisfactory. Nowadays, most academicians adoptthe method of HCDP to cure LN.④The study of modern medical science: It isconsidered that the incidence of LN is very complicated. It is in connectionwith genetic factors (genetic predisposing factors, etc), abnormal GMCproliferation and apoptosis, dysfunction of immunoregulation (imbalance ofcytokine network, declining ability to generate autoantibody like anti-ds-DNAantibody and anticardiolipin antibody and clean immune complex), as well asneural, endocrine and metabolic factors, etc. The abnormal generation andapoptosis of intrinsic glomerular cells such as GMC is an important mechanismof the incidence and evolvement of LN. Therefore, prevention and cure methodsare to inhibit proliferation and induce apoptosis of intrinsic glomerularcells like GMC. Therapeutic methods contain glucocorticoid, immunosuppressiveagent, other treatments such as plasmapheresis, immunoadsorption (IA),immunoglobulin, etc. But Western medical science-oriented therapy has manydisadvantages, such as non-standard therapeutic programs, insensitivity ordrug tolerance of some patients, considerable side effects, and so on.Therefore, researches focus on studying TCM therapeutic methods of tangibleeffects, economy and few side effects. (2)Clinical research: In the subjectgroup, the total effective rates of the disease and syndrome of TCM were 83.33%and 93.33% respectively. The effective rate of the disease was higher thanthe control group, but the difference had no statistical significance (P＞0.05). The effective rate of the syndrome was also higher compared with thecontrol group and the discrepancy was extremely significant (P＜0.01). In thesubject group, SLEDAI and the integral syndrome of TCM after therapy wereremarkably lower than before, and the discrepancies were extremely significant(P＜0.01). After therapy, the reduction of SLEDAI in the subject group wasmore satisfactory compared with the control group but the difference was notsignificant (P＞0.05); while the integral syndrome of TCM was remarkably lowerthan the control group, and the difference was extremely significant (P＜0.01). After therapy, main symptoms of the patients in the two groups wererelieved notably compared with symptoms before therapy and the differences were extremely significant (P＜0.01). In the subject group, the effect ofmoderating main symptoms of LN was better than the control group, but thediscrepancy was not significant (P＞0.05). Moreover, in the subject group,symptoms such as dysphoria, pharyngalgia, acne, menstrual clots, xerostomia,feverish sensation in palms and soles, tinnitus and cardiopalmus werealleviated more remarkably than the control group, and the difference wasextremely significant (P＜0.01). Regarding laboratory detection, in thesubject group, WBC, LYMN, HGB, PLT, ALB, C_3, C_4, CH_(50) rose notably after therapy,and the discrepancy was extremely significant (P＜0.01). Furthermore, ERY,PRO, ANA, ESR and FIB fell remarkably, and negative conversion of anti-ds-DNAantibody was visible. The discrepancies were extremely significant (P＜0.01)after treatment. The function of reducing ESR and converting anti-ds-DNAantibody to negative were better than the control group, and the differencewas significant (P＜0.05). (3)Empirical study:①The effects of serum oftype-ⅣLN patients on GMC: Different concentration (5%,10%,15% and 20%)serumof type-ⅣLN patients could promote GMC proliferation more markedly comparedwith control serum, and the difference was extremely significant (P＜0.01).The 15% serum of type-ⅣLN patients made the most significant impact.②Theeffects of traditional Chinese medicine of HCDP on GMC proliferation andapoptosis: Being intervened by the 15% serum of type-ⅣLN patients, differentconcentration (low, medium and high) serum containing traditional Chinesemedicine of HCDP could inhibit the proliferation of GMC and induce theapoptosis of GMC more notably than the control group, showing extremelysignificant difference (P＜0.01).The function indicated an obviousdose-effect relationship. The effect of high concentration serum was the mostnotable compared with other groups, the discrepancies were extremelysignificant (P＜0.01).③The synthesis of Bcl-2 protein and the expressionof Bcl-2mRNA in GMC: Being intervened by the 15% serum of type-ⅣLN patients,different concentration (low, medium and high) serum containing traditionalChinese medicine of HCDP could inhibit the synthesis of Bcl-2 protein and theexpression of Bcl-2mRNA, a gene inhibiting apoptosis, more remarkably thanthe control group. The function also showed an apparent dose-effectrelationship. The effect of high concentration serum was the most notable.
Conclusions (1)The pathogenesis of LN is very complicated. Abnormalproliferation and apoptosis of GMC is an important mechanism. Western medical science-oriented therapy has disadvantages such as insensitivity of somepatients, many side effects, etc. Studying traditional Chinese medicine thatcan inhibit GMC proliferation and induce GMC apoptosis is tremendouslypromising in clinical application. (2)Clinical research shows: TraditionalChinese medicine of HCDP can relieve main symptoms of LN of toxic heat andblood stagnation, improve laboratory detection indices, and reduce SLEDAI andthe integral syndrome of TCM. The therapeutic effects are satisfactory andthe side effects are fairly few. (3)Empirical study discovers: The serum oftype-ⅣLN patients can remarkably promote the proliferation of GMC and the15% serum has the most notable impact. Being intervened by the 15% serum oftype-ⅣLN patients, the serum containing traditional Chinese medicine of HCDPcan inhibit the proliferation of GMC, induce the apoptosis of GMC, and inhibitthe synthesis of Bcl-2 protein and the expression of Bcl-2mRNA, a geneinhibiting apoptosis remarkably. This may be the molecular mechanism of TCMof HCDP curing LN and provides experimental and theoretical evidence forclinical application.
引文
[1] 王海燕主编．肾脏病学，人民卫生出版社，2001，2：421-430
[2] 叶任高，张道友，刘冠贤主编．红斑狼疮，人民卫生出版社，2003，1
[3] 蔡光先，赵玉庸主编．中西医结合内科学，中国中医药出版社，2005，1
[4] 曹阳．王明如治疗狼疮性肾炎的经验．吉林中医药，2003；23(3)：3-4
[5] 刘玉宁，邓跃毅，王立红．陈以平教授治疗狼疮性肾炎的经验．中国中西医结合肾病杂志，2003；4(8)：437-438
[6] 盛梅笑，王身菊．狼疮性肾炎中医临床证候分型的调研分析．江苏中医药，2004；25(4)：12-14
[7] 柯凌．叶任高教授治疗狼疮性肾炎的思路与经验．中国中西医结合肾病杂志，2001；2(4)：190-191
[8] 盛梅笑，王钢．狼疮性肾炎中医病机与治法探讨．中国中医基础医学杂志，2003；9(12)：55-57
[9] 王济东，赵春荣，郑少同等．雷公藤多甙对狼疮性肾炎患者血浆IL-13含量的影响．现代中西医结合杂志，2004；13(22)：2952-2953
[10] 李燕红，张庆怡．雷公藤多甙片治疗狼疮性肾炎的性激素变化及疗效关系．中国中西医结合肾病杂志，2002；3(5)：278-279
[11] 许晨，吴兆龙，张志刚等．雷公藤红素对狼疮鼠肾小球Ⅰ和Ⅳ型胶原的影响．中华风湿病学杂志，2002；6(4)：235-238
[12] 许晨，吴兆龙，张志刚等．雷公藤红素对狼疮鼠肾组织Ⅲ型胶原和层粘素的影响．肾脏病与透析肾移植杂志，2002；11(2)：106-109
[13] 闫承菊，王凯，祝玉范．火把花根片六味地黄丸并用治疗狼疮性肾炎16例．实用中医内科杂志，2003；17(3)：217-218
[14] 周丽华，张碧芬，姚春萌等．从细胞免疫变化探讨百令胶囊对狼疮性肾炎的作用．中国药师，2004；7(4)：289-290
[15] 梁鸣，李幼姬，阳晓等．中药狼疮方对狼疮样小鼠外周血IL-6和IL-10水平的影响．中国中西医结合肾病杂志，2001；2(9)：502-504
[16] 温成平，范永升，黄永凯等．中药狼疮定对系统性红斑狼疮外周微循环的研究．中国中西医结合肾病杂志，2002；3(12)：704-706
[17] 陈爱平，熊佩华，李福民等．狼疮静加减对狼疮性肾炎患者血粘附分子、肾小球肾小管标志蛋白的影响．中华实用中西医杂志，2004；4(17)：3555-3557
[18] 朱方石，金实，汪悦等．狼疮静颗粒对自发性狼疮小鼠狼疮样改变抑制作用的实验研究．中国中西医结合杂志，2004；24(4)：343-347
[19] 陈湘君，母小真，顾军花等．补肾固精方治疗狼疮性肾炎的疗效观察．上海中医药大学学报，2003：17(1)：23-24
[20] 林德就，温伟平，邱仁斌等．加味猪苓汤配合复方丹参注射液治疗系统性红斑狼疮性肾炎30例疗效观察．新中医，2003：35(7)：26-27
[21] 王思平，陈红，陈明龄．狼疮颗粒对AHN模型大鼠肾脏组织病理学的影响．中药药理与临床，2003；19(1)：28-30
[22] 林有坤，郑文军，吴易等．雄黄对狼疮鼠肾功能的近期影响．广西医科大学学报，2003：20(6)：878-881
[23] 贾乐文，王丹阳．白芍总甙治疗狼疮性肾炎2例．中国中西医结合肾病杂志，2003；4(3)：127
[24] 汪华林，叶任高，李幼姬等．川芎嗪对活动期狼疮性肾炎外周血单个核细胞B7-1和B7-2mRNA表达的影响．中国中西医结合肾病杂志，2001：2(5)：262-265
[25] 夏育民，徐世正．大黄素对狼疮样BXSB小鼠的影响．华中医学杂志，2003：27(2)：63-64
[26] 卢岚．冬虫夏草和青蒿素抑制狼疮性肾炎复发的研究．中国中西医结合杂志，2002：22(3)：169-171
[27] 朱卫星，顾军．青蒿琥酯对狼疮样小鼠肾脏白介素6和转化生长因子β的影响．中国中西医结合皮肤性病学杂志，2003：2(1)：25-27
[28] 董妍君，李卫东，屠呦呦等．双氢青蒿素对BXSB狼疮小鼠自身抗体产生、TNF α分泌及狼疮性肾炎病理改变的影响．中国中西医结合杂志，2003：23(9)：676-679
[29] 关明媚，傅君舟，郭群英等．黄芪与丹参注射液联合治疗狼疮肾炎的临床观察．中国中西医结合肾病杂志，2003；4(9)：529-531
[30] 沈良兰．黄芪注射液治疗狼疮性肾炎的临证体会．中国中西医结合肾病杂志，2003；4(7)：419-420
[31] 高峰，赵立新．蜂针疗法配合治疗狼疮性肾炎25例疗效观察．山西中医，2004：20(4)：31
[32] 龚如军，刘志红，陈朝红等．PAI-1基因和纤维蛋白原β链基因多态性与狼疮性肾炎肾小球微血栓的关系．中华医学遗传学杂志，2002；19(1)：1-5
[33] 刘志红，吴燕，周虹等．不同增殖性肾炎细胞增殖与凋亡的关系．中华肾脏病杂志．1997：13(6)：334
[34] 潘晓勤，王晓燕，姜新猷．肾小球系膜细胞培养及鉴定．南京医科大学学报，1995：15(1)：222-223
[35] 王景明，孙奕，叶传蕙．肾衰宁灌肠液对体外培养的人肾小球系膜细胞增殖及产生纤维连接蛋白的影响．中国中西医结合急救杂志，2000：7(6)：353-355
[36] 宋纯东，丁樱．雷公藤多甙对系膜增生性肾炎系膜细胞凋亡及其调控基因Fas／Fas L影响的实验研究．中医药学刊，2003；21(7)：1130-1131
[37] 杨桢华．细胞凋亡及Bcl-2、Bax与狼疮性肾炎．广西医学，2005：27(1)：90-93
[38] 邱明山，阮诗玮，王智等．狼疮肾炎患者外周血淋巴细胞凋亡调控因子和血清尿白细胞介素-8的变化．中华风湿病学杂志，2004；8(1)：20-22
[39] 杨桢华，孙安远，廖蕴华等．B细胞淋巴瘤／白血病-2蛋白在狼疮性肾炎肾组织表达及意义．临床荟萃，2004；(19)20：1144-1147
[40] 刘亚光，尹培达，赵湘如，等．系统性红斑狼疮患者Bcl-2蛋白的表达及其临床意义．中华内科杂志，1999；38(2)：94-97
[41] Walport MJ. Complement and systemic lupus erythematosus[J]. Arthritis Res, 2002;4(Suppl 3) : S279-293
[42] 孙铀，赵阴环，张凤山．C1q抗体在狼疮性肾炎诊断中的意义．诊断学理论与实践，2004；3(4)：251-253
[43] 蔡小燕，杨岫岩，陈小辉等．血清C1q抗体对评价狼疮肾炎活动性及疗效的临床意义．中华医学杂志，2004；84(17)：1436-1439
[44] 钟清，唐萸香，谯林等．狼疮性肾炎患者抗心磷脂抗体的测定及其临床意义．重庆医科大学学报，2003；28(1)：11-13
[45] Hammond A, Rudge AC, Loizou S, et al. Reduced number of complement receptor type 1 on erthrocytes are associated with inceased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythmatosus and the antiphospholipid syndrome. Arthritis Rheum, 1989;32(3):259-264
[46] Von scheven E, Athreya B, Rose C, et al. Clinical characteristics of antiphospholipid antibody syndrome in children. J Pediatr, 1996;129(3):339-345
[47] Frampton G, Hicks J, Cameron JS. Significance of antiphospholilid antibodies in patients with lupus nephritis. Kidney Int, 1991;39(3):1125-1231
[48] 中华医学会风湿病学分会．系统性红斑狼疮诊治指南(草案)．中华风湿病学杂志，2003；7(8)：508-513
[49] Ballardie FW, Brenchley PE, Williams S, et al. Autoimmunity in IgA nephropathy. Lancet, 1988;2:588-592
[50] O' Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schonlein purpura, J Clin Invest, 1991;88:1522-1530
[51] 裴斐，赵明辉，汪莺昱等．狼疮肾炎中新发现的抗肾小球系膜细胞抗体靶抗原的鉴 定．中华医学杂志，2004；84(3)：194-198
[52] 陈曼，汪莺昱，赵明辉等．狼疮肾炎患者血清抗系膜细胞抗体及其靶抗原的研究．中华内科杂志．2003；42(12)：851-853
[53] Egiloj, Gomez-Chiarrim, Ortiza, et al. Role of tumor necrosis factor-α in pathogenesis of glomerular diseases. Kidney Int, 1993;43(Suppl 39):S 59-64
[54] 范兴忠，李新东，潘宝安等．TNF检测在环磷酰胺治疗狼疮性肾炎中的价值．免疫学杂志，2000；16(3)：218-220
[55] 周树录，叶任高，刘晓波等．Fc受体γ链基因启动子区29位点基因多态性与系统性红斑狼疮关系的研究．中国病理生理杂志，2003；19(6)：782-785
[56] 周燕斌，叶任高，谢灿茂等．CD134及核因子-κB在狼疮性肾炎肾组织的表达及意义．中山大学学报(医学科学版)，2003；24(3)：224-228
[57] 许韩师，叶任高，张式鸿等．核因子-κB在狼疮肾炎肾组织中的表达及其意义．中华肾脏病杂志，2000；16(4)：230-233
[58] 朱丽晶，刘志红，曾彩虹等．白介素-10基因多态性与狼疮性肾炎的关系．肾脏病与透析肾移植杂志，2004；13(2)：113-118
[59] 张肇，陈孝文，江黎明等．狼疮肾炎患者白细胞介素13的血浆水平和基因表达．中华肾脏病杂志，2000；16(1)：20-23
[60] 梁科，刘华锋，廖丽琼等．狼疮肾炎患者Th1／Th2细胞因子失平衡状况的研究．中华风湿病学杂志，2004；8(11)：671-675
[61] 董光富，叶任高，陈雄辉等．白介素17的表达与狼疮肾炎关系初探．中华风湿病学杂志，2001；5(3)：152-155
[62] Wong CK, Ho CY, Li EK, et al. Elevation of proinflammatory cytokine(IL-1 8, IL-17, IL-12) and Th2 cytokine (IL-4) concentrationsin patients sys temic lupus erythematosus. Lupus, 2000;9(8):589-593
[63] 董光富，叶任高，潘云峰等．狼疮肾炎患者外周血单个核细胞IL-17信号转导途径的初步研究．中国病理生理杂志，2004；20(8)：1353-1359
[64] 董光富，叶任高，孔庆喻等．GMP-140水平与狼疮肾炎肾损害的相关性．中山医科大学学报，2000；21(3)：193-195
[65] 梁鸣，李幼姬，阳晓等．RANTES在狼疮肾炎肾组织中的表达及其意义．中华风湿病学杂志，2002；6(3)：161-165
[66] Carreno BM, Collins M. The B? family of ligands and its receptors:new pathways roy costimulation and inhibition of immunol response. Annu Rev Immunol, 2002; 20:29-53
[67] 丁涵露，吴雄飞，刘宏等．Ⅳ型狼疮肾炎患者肾组织中程序性死亡配体-1—程序性 死亡-1的表达及其意义．中华风湿病学杂志，2004；12(8)：723-727
[68] 王俭勤，李幼姬，王文革等．雌激素刺激活动性狼疮肾炎外周血单个核细胞的IL-10表达．基础医学与临床，2003；23(5)：562-565
[69] Jiang T, Liu S, Tan M et al. The phase shift mutation in the glucocorticoid receptor gene:potential etiologic significance of neuroendocrine machnisms in lupus nephritis. Clin Chim Acta, 2001;313(12):133-137
[70] 李海坚，刘华锋，潘志铣等．地塞米松对狼疮性肾炎患者外周全血培养细胞IL-12，IFN-γ分泌水平的影响．中国现代医学杂志，2003；13(5)：85-87
[71] 张冬梅，顾华，孙广东等．甲基强的松龙对狼疮性肾炎患者血浆中PAI-1的影响．中国免疫学杂志，2003；19：355-356
[72] 耿丽芬，朱建君，于有山等．甲基强的松龙冲击治疗重症狼疮性肾炎．中国中西医结合肾病杂志，2002；3(12)：727
[73] 白云凯，肖桦，陈华蓉等．环磷酰胺和激素对Ⅳ型狼疮性肾炎患者尿白介素-8的影响．临床荟萃，2000；15(13)：595-596
[74] 薛鸾，胡建东．不同的环磷酰胺冲击方案对狼疮性肾炎的影响．临床荟萃，2000；15(12)：547-548
[75] 庄宁宁，薛志强．分阶段环磷酰胺冲击治疗狼疮性肾炎．广东医学，2003；24(5)：461-463
[76] Mok CC，et al．弥漫增生型狼疮性肾炎的治疗：两种含环磷酰胺方案的比较．医学信息，2002；15(3)：191
[77] 狄伟南．狼疮性肾炎两种治疗方案的疗效比较．徐州医学院学报，2002；22(6)：538-541
[78] 张益民，李幼姬．弥漫增殖性狼疮肾炎的治疗．Am J Kidney Dis，2004；43(2)：197-208
[79] 刘志红，黎磊石．霉酚酸酯在重症狼疮性肾炎中的应用．肾脏病与透析肾移植杂志，2002；11(6)：537-538
[80] Gaubitz M, Schoral A, Schotte H, et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus. An open pilot trail lupus, 1999;(8):731-736
[81] 丁磊，赵明辉，邹万忠等．霉酚酸酯联合激素对弥漫增生性狼疮肾炎活动性及慢性病变的影响及其机制研究．中华肾脏病杂志，2002；18(1)：9-13
[82] Yu C C, Yang C W, WuMS. et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomorulosclerosis in MRL/1primice. J Lab Clin Med, 2001;138(1):69
[83] 许晨，吴兆龙．麦考酚酸酯对狼疮性肾炎小鼠肾小球硬化的防治．中国临床药学杂 志，2002；11(1)：19-22
[84] 陈香美，刘文虎，蔡广研等．霉酚酸酯对MRL-1pr／1pr小鼠狼疮性肾炎的治疗作用．中华微生物学和免疫学杂志，2002；22(1)：82-87
[85] 梅长林，张维莉．霉酚酸酯在非移植性肾脏疾病中的应用．肾脏病与透析肾移植杂志，2002；11(6)：539-540
[86] 刘思明，吴文红，叶任高等．环孢素A联合环磷酰胺治疗狼疮肾炎的疗效观察．中国药物与临床，2003；3(3)：200-202
[87] Jiang H, Yang X, Soriano RN, et al. Distinct patterns of cytokine gene suppresion by the equivalent effective doses of cyclosporine and tacrolimus in rat heart allografts. Immunobiology, 2000;202(3):280
[88] 陈强，刘志红，胡伟新等．普乐可复治疗Ⅳ型狼疮性肾炎的前瞻性临床研究．肾脏病与透析肾移植杂志，2002；11(4)：301-307
[89] 刘玉春，赵明辉，邹万忠等．普乐可复治疗弥漫增殖性狼疮肾炎5例临床病理观察．中国实用内科杂志，2004；24(3)：175-176
[90] Pelera P, Manger B, Manger k, el al. A pilot study of leflunomide in systemic lupus erythematosus. Arthritis Rheum, 2000;43(Suppl)241
[91] 张凤山，聂英坤，孙铀等．来氟米特治疗狼疮肾炎疗效分析．中华风湿病学杂志，2004；8(2)：73-76
[92] 陈宜恒．来氟米特与环磷酰胺治疗狼疮性肾炎对比观察．中国误诊学杂志，2003；3(10)：1508-1509
[93] Buumpas DT, Tassiulas IO, Fleisher TA, et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephril, 1999;52:67
[94] 严东海，赵丽娟，李曼等．双重膜滤过式血浆置换治疗重症活动性狼疮性肾炎．中华肾脏病杂志，2000；16(6)：402
[95] 潘丽萍，杨尽梅，韦颖等．免疫吸附在重症狼疮性肾炎患者中的应用．肾脏病与透析肾移植杂志，2002；11(6)：514-518
[96] 邓行江，李荣藻，黄洁平．不同剂量静脉注射免疫球蛋白辅助治疗狼疮性肾炎临床观察．临床医学，2003；23(10)：50-51
[97] 郑筱萸主编．中药新药临床研究指导原则，中国医药科技出版社，2002，1：111-115
[98] 王汉民．免疫抑制剂在狼疮性肾炎治疗中的应用．现代医学，2003；31(6)：351-353
[99] 吗替麦考酚酯在肾内科应用专家协作组．吗替麦考酚酯在肾内科应用的指导意见．中华肾脏病杂志，2004；20(5)：385
[100] 陈惠萍，曾彩虹，胡伟新等．10594例肾活检病理资料分析．肾脏病与透析肾移植杂志，2000；9(6)：501
[101] 王本祥．现代中药药理学，天津：天津科学技术出版社，1998，1：8
[102] 时振声．时氏中医肾脏病学，北京：中国医药科技出版社，1997，1：80
[103] 王海颖．陈以平教授治疗狼疮性肾炎的经验．新中医，2001；33(9)：9
[104] 洪钦国，汤水福．肾脏病诊断治疗学，广州：广东科技出版社，2001，1：116
[105] 周翠英．系统性红斑狼疮．山东中药杂志，1995：14(7)：317-320
[106] 施新猷主编．现代医学实验动物学，北京：人民军医出版社，2000，1：335
[107] 王钢，刘丽，朱晓雷等．保肾片对人系膜细胞增殖、凋亡和细胞周期的影响．中国中西医结合肾病杂志，2002；3(8)：442-444
[108] Urowitz MB, Gladman DD, et al. The lupus activity criteria count. J Rheum, 1984;11:783
[109] 解放军肾脏病研究所学术委员会．狼疮性肾炎的诊断及治疗．肾脏病与透析肾移植杂志，2004；13(2)：168-171